Document Detail


A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection.
MedLine Citation:
PMID:  23019296     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
SUMMARY ANSWER: Equivalence of treatments in terms of ongoing live intrauterine pregnancy rate has not been demonstrated; the 95% confidence interval (CI) for the difference in ongoing pregnancy rate (-8.2 to 0.1%) did not lie entirely within the pre-specified equivalence interval -7 to 7%.
WHAT IS KNOWN ALREADY: No significant differences in clinical pregnancy rates have been observed between vaginal progesterone gel and other vaginal progesterone products in earlier studies. However, all previous studies included a limited number of patients.
STUDY DESIGN, SIZE AND DURATION: This was a randomized, multicentre, controlled, assessor-blinded equivalence trial in 18 fertility centres in Denmark and Sweden between March 2006 and January 2010. A web-based randomization program was used with concealed allocation of patients. Patients were randomized to one of two groups: vaginal progesterone gel or vaginal micronized progesterone tablets. There was no blinding of patients.
PARTICIPANTS AND SETTING: A total of 2057 women ≤ 40 years of age were included and down-regulated, using the long agonist protocol and rFSH for stimulation. Luteal support was given for 19 days after embryo transfer or until a negative pregnancy test Day 14 after embryo transfer. Patient convenience was assessed using questionnaires to be filled in 14 days after embryo transfer, before pregnancy test.
MAIN RESULTS AND THE ROLE OF CHANCE: Ongoing intrauterine pregnancy rates were 299/991 (30.2%) (95% CI 27.3-33.0%) in the progesterone gel group and 324/992 (32.7%) (29.7-35.6%) in the micronized progesterone tablet group. The difference in ongoing pregnancy rates between the groups was -4.1% (-8.2 to 0.1%) and the difference in live birth rates was -3.4% (-7.4 to 0.7%), both calculated after correction for significant confounders. Patient convenience and ease of use (1 = very convenient, 10 = very inconvenient) was in favour of progesterone gel, as the overall score was 2.9 (2.7-3.0) for progesterone gel and 4.8 (4.7-5.0; P < 0.0001) for micronized progesterone tablets. This large equivalence trial shows that, even though equality could not be demonstrated, there is no substantial difference in ongoing pregnancy rate between vaginal progesterone gel and vaginal micronized progesterone tablets. It also shows that progesterone gel is considered more convenient by the patients.
BIAS, CONFOUNDING AND OTHER REASONS FOR CAUTION: Blinding of patients was not possible in this study, but since the outcome (pregnancy) is robust, blinding would have been unlikely to affect the results. Unfortunately, owing to an error in the randomization, the intended age distribution allocated older women to the micronized progesterone tablet group. In the analysis of results, adjustments were made for age and number of embryos transferred.
GENERALIZABILITY TO OTHER POPULATIONS: The results can be generalized to other women ≥ 18 and ≤ 40 years of age undergoing IVF/ICSI who have regular menstrual cycles (25-35 days), both ovaries present and no more than two previous failed IVF attempts.
STUDY FUNDING/COMPETING INTEREST: Merck Serono supported the study but had no influence on the design of the study and was not involved in the analysis of the results or preparation of the manuscript.
TRIAL REGISTRATION NUMBER: The trial was issued with the EudraCT number 2005-001248-22 with the Protocol code number 95576471.
Authors:
Christina Bergh; Svend Lindenberg;
Related Documents :
23450526 - Anti-d administration in pregnancy for preventing rhesus alloimmunisation.
24832366 - Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a sy...
9408866 - Terbutaline pump tocolysis in high-order multiple gestation.
8821026 - Antepartum management of the multiple gestation: the case for specialized care.
1713496 - Spontaneous activity in vitro of the uterine horns of unilaterally pregnant rats. relat...
6159566 - Amniotic fluid alpha-fetoprotein in fetal obstructive uropathy.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-09-27
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  27     ISSN:  1460-2350     ISO Abbreviation:  Hum. Reprod.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-20     Completed Date:  2013-04-29     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  England    
Other Details:
Languages:  eng     Pagination:  3467-73     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Reproductive Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. christina.bergh@vgregion.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Denmark
Embryo Transfer / methods
Female
Fertilization in Vitro / methods*
Humans
Luteal Phase / drug effects
Patient Satisfaction
Pregnancy
Pregnancy Rate
Progesterone / administration & dosage*
Sperm Injections, Intracytoplasmic / methods*
Sweden
Vaginal Creams, Foams, and Jellies
Chemical
Reg. No./Substance:
0/Vaginal Creams, Foams, and Jellies; 57-83-0/Progesterone
Investigator
Investigator/Affiliation:
Svend Lindenberg / ; Finn Hald / ; Anders Nyboe Andersen / ; Michael Aasted / ; Jeanette Wullf Bogstad / ; Sven Skouby / ; Anette Lindhard / ; Peter Humaidan / ; Anders Faurskov / ; Faurskov Fertilitet / ; Sven Rex / ; Anne-Lis Mikkelsen / ; Holbaek Sygehus / ; Hans Krog / ; Emil Rasmussen / ; Christina Bergh / ; Ann Thurin-Kjellberg / ; Karin Rova / ; Leif Bungum / ; Kjell Wånggren / ; Nils-Gunnar Solensten /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adverse Cardiac Remodeling: Phosphoinositide 3-Kinase, Another Unique Factor in a Multifactorial Con...
Next Document:  The follicular hormonal profile in low-responder patients undergoing unstimulated cycles: Is it hypo...